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DNA methylation-dependent gene silencing is one of the
most characterized mechanisms in epigenetic regulation of
gene expression. This process is thought to influence the
ability of hepatocyte nuclear factor 1 (HNF1) to transactivate
organic anion transporter expression in the liver and kidney.
To evaluate this further we profiled 282 mouse solute carrier
transporters by examining regions near their transcription
start sites for tissue-dependent differentially methylated
regions (T-DMR) using restriction tag-mediated amplification
to determine T-DMR disparity between the liver and kidney.
Forty-two of these were associated with T-DMR tags
hypomethylated in the kidney but hypermethylated in the
liver. Computational analysis found a canonical HNF1-
binding motif within 1 kbp of the promoter region of
13 carriers including the amino acid transporters Slc6a19,
Slc6a20, Slc7a8 and Slc7a9; all expressed predominantly in
the kidney. Bisulfite genomic sequencing found that CpG
dinucleotides neighboring the T-DMR tags were
hypomethylated in the kidney compared with the liver.
The Hnf1a promoter region itself contained a T-DMR
hypomethylated in the liver and kidney but hypermethylated
in the cerebrum, consistent with the tissue distribution of
Hnf1a. Taken together, our results show a central role of DNA
methylation in the kidney-specific expression of amino acid
transporters thus determining both the tissue distribution
of their master regulator, Hnf1a, and its interaction with
downstream genes.
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Transporters are membrane-integrated proteins expressed in
the lipid bilayers of cellular surface or intracellular organelles,
such as mitochondria, where they mediate the transmembrane
transport of endogenous and exogenous compounds as well as
inorganic ions. It is considered that at least 5% (42000) of all
human genes are transporters or transporter-related proteins.1
Among the transporters, the solute carrier (SLC) family
comprises more than 300 facilitated and secondary active
transporters and accounts for a significant portion of all
transporter-related proteins in the genome. The physiological
and pathological significance of SLC transporters has been
clarified in terms of their tissue distribution, substrate
specificity, and link to some human genetic diseases.2
The tissue distribution has critical implication in the
physiological and pathological function of transporters.3,4
Some transporters are expressed exclusively in a certain
tissue, where they exert a specific function (for example,
elimination of xenobiotics and reabsorption of nutrients in
the liver and kidney). Cumulative evidence suggests a role of
DNA methylation-dependent gene silencing, one of the most
characterized mechanisms in epigenetic regulation, in spatio-
temporal gene expression in mammals.5–7 We have shown
previously that the kidney-specific expression of organic
anion transporter 3/SLC22A8 and urate transporter
1/Slc22a12 is accomplished by epigenetic regulation mediated
by DNA methylation. The mRNA expression of organic
anion transporter 3 can be induced in the organic anion
transporter 3-negative cell lines, Caco-2 and HEK293 cells, by
inhibiting DNA methylation in the presence of endogenous
or exogenous hepatocyte nuclear factor 1 (HNF1), an
indispensable transactivator for the expression of organic
anion transporters in the liver and kidney.8 A tissue-
dependent differentially methylated region (T-DMR) was
found in vivo surrounding the HNF1-binding motif in the
promoter region of urate transporter 1, and this T-DMR is
hypomethylated in the kidney but hypermethylated in the
liver.9 A similar mechanism was later proposed for
the expression of organic cation transporter 2/SLC22A2
in the kidney.10 DNA methylation hampers the binding
of transcription factor upstream stimulating factor 1 to
its recognition motif in the organic cation transporter
2 promoter. However, the DNA methylation profile of most
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SLC transporters in the liver and kidney remains an open
question.
Several groups, including our group, have shown the
significance of HNF1a in the transcriptional regulation of
SLC transporters expressed exclusively in the liver or kidney.
The promoter activities of human organic anion transporting
polypeptide (OATP) and OAT family transporters are
stimulated by HNF1a.8,9,11,12 Consistent with these in vitro
results is the observation that mRNA expression of OATP
family transporters in the liver and OAT family transporters
in the kidney is impaired in Hnf1a-null mice.13,14 Hnf1a-null
mice also manifest the renal Fanconi syndrome, characterized
by the defect in renal reabsorption of filtered solutes such as
glucose, phosphate, urate, and amino acids, which can be
ascribed to the decreased expression of renal transporters
responsible for the reabsorption process.9,15–17
Based on our previous study of organic anion transporter
3 and urate transporter 1, we postulated that T-DMRs
influence the interaction of HNF1a with its recognition
sequences in the promoter region of SLC transporters in a
tissue-dependent manner, and thereby establish and maintain
the tissue-specific transport systems. We recently developed a
novel methodology, named T-DMR profiling with restriction
tag-mediated amplification (D-REAM), to analyze the DNA
methylation profiles of the genomic region, from 6.0 to
þ 2.5 kbp relative to the transcriptional start site (TSS) of
approximately 30,000 genes, which was covered by a mouse
promoter-tiling array.18 The objective of this study was to
elucidate the relevance of DNA methylation profiles in the
kidney-specific expression of SLC transporters by the
comprehensive analysis of DNA methylation status around
the TSS of almost all mouse SLC transporters using D-REAM
in the liver and kidney, where Hnf1a is abundantly expressed.
Our data show that SLC transporters, whose promoter or
intronic regions possess T-DMRs and canonical HNF1-
binding motif, include kidney-specific amino-acid transporters.
RESULTS
Identification of SLC transporters with the T-DMR tag and
HNF1-binding motif
To identify the genes of which mRNA expression is regulated
by DNA methylation in the liver and kidney, we searched the
presence of T-DMR tags between these two tissues in
approximately 6.0 to þ 2.5 kbp around the TSS of almost
all mouse genes (30,120 Ensembl mouse genes) using
D-REAM. We found that 3674 genes possessed T-DMR tags
that were hypomethylated in the liver and hypermethylated in
the kidney, and particularly, 50 of them were annotated as
SLC transporter genes. In contrast, 2660 genes, including
42 SLC transporter genes, were associated with T-DMR tags
that were hypomethylated in the kidney and hypermethylated
in the liver (Supplementary Table S1). The presence of
a canonical HNF1-binding motif in the promoter region up
to 1.0 kbp of these SLC transporter genes was examined
using g:Profiler. HNF1-binding motifs were located in the
promoter region of 18 of 50 and 13 of 42 SLC transporter
genes with hypomethylated T-DMR tags in the liver and
kidney, respectively (Table 1).
mRNA expression of SLC transporters with the T-DMR tag
and HNF1-binding motif
The mRNA expression levels of SLC transporters with the
T-DMR tag and HNF1-binding motif in the liver and kidney
were obtained from the mRNA expression database GNF
SymAtlas and plotted in a logarithm graph (Figure 1). The
in silico screening successfully identified the liver- or kidney-
specific SLC transporters that might be regulated by DNA
methylation and Hnf1 at the transcriptional level. The liver-
specific transporters, which showed more than twofold
higher mRNA expression in liver than in kidney, included
Ntcp/Slc10a1 and Oatp1b2/Slco1b2, which have major roles
in the uptake of bile acids from the systemic circulation into
hepatocytes in an Naþ -dependent and independent manner,
respectively.19 Oatp1b2 also functions in the elimination
pathway of xenobiotics, particularly amphipathic organic
anions, with structural diversities.20 The four transporters
with more than twofold higher expression in the kidney than
in the liver were amino-acid transporters, B0AT1/Slc6a19,
XT3/Slc6a20, LAT2/Slc7a8, and b0,þAT/Slc7a9. These trans-
porters are responsible for the renal reabsorption of amino
acids filtered from the blood circulation through the
glomeruli and into the urine.21
DNA methylation profiles of amino-acid transporters
The comparative microarray signals of D-REAM analysis
were displayed on an integrated genome browser plot that
focused on the four amino-acid transporters with T-DMR
tag. The DNA methylation profiles of the CpG dinucleotides
neighboring the T-DMR tags were determined further
by bisulfite genomic sequencing in the liver and kidney
(Figure 2a). Most of the CpG dinucleotides analyzed were
significantly hypomethylated in the kidney compared with
the liver, which is compatible with the kidney-specific
expression of these amino-acid transporters.
In addition to the above-mentioned four amino-acid
transporters, EAAC1/Slc1a1, rBAT/Slc3a1, 4F2hc/Slc3a2, and
yþLAT1/Slc7a7 also constitute the renal reabsorption process
of amino acids.21 Among them, EAAC1, rBAT, and yþLAT1
are expressed predominantly in the kidney and small
intestine, whereas 4F2hc is a ubiquitous transporter. When
the comparative microarray signal of D-REAM was examined
throughout the whole genomic region of these transporters,
T-DMR tags relatively hypomethylated in the kidney
compared with the liver were detected more than 2.5 kbp
downstream and 6.0 kbp upstream of the TSS of Ensembl
transcripts for Slc1a1 and Slc7a7, respectively (Figure 2b).
The TSS of the RefSeq transcript for Slc7a7 (NM_011405),
which is far from that of the Ensembl transcript
(ENSMUST00000000984), was near the T-DMR tag, indicat-
ing that this T-DMR tag is associated with the longer
transcript. Because the microarray signal associated with
the 50-upstream region of Slc3a1 was slightly greater than the
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basal level, which had not reached the statistical criteria
of T-DMR tag, bisulfite genomic sequencing was carried
out to find T-DMR in this region. Three CpG dinucleotides
at 1856, 1801, and 1718 relative to the TSS were
found to be relatively hypomethylated in the kidney
compared with the liver (Figure 2b). No significant T-DMR
tag was observed throughout the genomic region en-
compassing Slc3a2. The positions of these further-identified
T-DMR tags and HNF1-binding motifs in the promoter
up to 1.0 kbp are included in Table 1. These results suggest
that the kidney-specific expression of most of the amino-acid
transporters is associated with the presence of the T-DMR
and HNF1-binding motif in the genomic region around
the TSS.
Histone acetylation profiles around the transcriptional start
site of amino-acid transporters
It is generally understood that DNA methylation evokes the
chromatin remodeling events, including the deacetylation of
histone H3, and thus repress the mRNA expression of
neighboring genes. In order to investigate the functional
importance of DNA methylation in the tissue-specific
expression of B0AT1/Slc6a19, XT3/Slc6a20, LAT2/Slc7a8,
and b0,þAT/Slc7a9, a chromatin immunoprecipitation assay
was used to quantify the acetylation of histone H3 around the
TSS of these genes in the liver and kidney (Figure 3). Histone
H3 was highly acetylated in the kidney compared with the
liver around the TSS of Slc6a19, Slc6a20, and Slc7a9, which is
in good agreement with the kidney-specific expression of
Table 1 | SLC transporters with T-DMR tag between the liver and kidney and HNF1-binding motif in the promoter region
Position of T-DMR tags and HNF1-binding motifs relative to the TSS of each RefSeq
Gene name Protein name Refseq ID T-DMR tag HNF1-binding motif
T-DMRtag (liver4kidney)
Slc1a4 Asct1 NM_018861 +1208, +1243 964/948
Slc6a5 Glyt2 NM_148931 1143 569/553
Slc6a13 Gabt3 NM_144512 +1545 584/568, 459/443, 446/430
Slc7a2 Cat2 NM_007514 4254, 3061 476/460
Slc7a12 Asc-2 NM_080852 +1310 139/123, 65/49
Slc10a1 Ntcp NM_011387 +495 970/954, 872/856
Slc12a1 Nkcc2 NM_183354 1977, 1553 790/774, 211/195, 193/177
Slc16a10 TAT1 NM_028247 +2433 760/744, 306/290, 232/216
Slc17a2 Npt3 NM_144836 +1958 844/828, 118/102
Slc25a15 Ornt1 NM_011017 +2451 847/831
Slc25a27 Ucp4 NM_028711 5174, 4435,
4431
986/970, 974/958, 957/941
Slc26a9 NM_177243 +182, +222 35/19
Slc29a2 Ent2 NM_007854 1630, 1309 450/434
Slc30a8 ZnT-8 NM_172816 4852 373/357
Slc35b1 Ugalt2 NM_016752 +1045 691/675, 210/194
Slc35d2 Hfrc NM_001001321 1792 779/763
Slc39a1 Zip1 NM_013901 2655, 2238 731/715, 461/445
Slco1b2 Oatp1b2 NM_020495 515 409/393, 67/51
T-DMRtag (kidney4liver)
Slc1a1* EAAC1 NM_009199 +34741 1004/988, 955/939
Slc1a4 Asct1 NM_018861 5518 964/948
Slc3a1* rBAT NM_009205 (1856) 658/642, 70/54
Slc5a4b Sglt3-b NM_023219 +2281 870/854, 676/660, 630/614, 462/446, 353/
337
Slc6a19 B0AT1 NM_028878 1080 126/110
Slc6a20 XT3 NM_011731 478 909/893, 828/812, 794/778, 232/216
Slc7a7* y+LAT1 NM_011405 2712, 2067 (1508/1492)
Slc7a8 LAT2 NM_016972 4956, +1622 726/710, 168/152
Slc7a9 b0,+AT NM_021291 +1021 169/153
Slc10a2 Asbt NM_011388 4199 614/598, 440/424, 280/264, 231/215, 222/
206
Slc13a2 NaDC-1 NM_022411 +167 710/694, 103/87
Slc17a2 Npt3 NM_144836 3324, 3315 844/828, 118/102
Slc25a15 Ornt1 NM_011017 5669 847/831
Slc29a2 Ent2 NM_007854 735 450/434
Slc30a7 ZnT-7 NM_023214 2948 833/817, 817/801, 306/290
Slco1a1 Oatp1a1 NM_013797 +2678 911/895, 889/873, 466/450, 271/255, 75/59
Abbreviations: HNF1, hepatocyte nuclear factor 1; RefSeq, reference sequence; SLC, solute carrier; T-DMR, tissue-dependent differentially methylated regions; TSS,
transcription start site.
Common abbreviations for each gene product are provided wherever possible. Asterisks indicate transporters where T-DMR tags were located either by examining the
microarray signal of restriction tag-mediated amplification throughout the whole genomic region or by directly determining the DNA methylation profiles (see Figure 2b).
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these amino-acid transporters. On the other hand, acetylated
histone H3 was observed both in the liver and in the kidney
around the TSS of Slc7a8. Histone H3 in the b-actin
promoter was hyperacetylated in both tissues.
DNA methylation profile of the promoter region of Hnf1a
We have shown previously that the promoter region of Hnf1a
is hypomethylated in the liver but hypermethylated in the
cerebrum.18 As Hnf1a is also expressed in the kidney, where
it is indispensable for the promoter activation of many SLC
transporters, the DNA methylation status of the Hnf1a
promoter in the kidney was investigated. Bisulfite genomic
sequencing showed clearly that the promoter region is
hypomethylated in the kidney as well as in the liver,
but hypermethylated in the cerebrum (Figure 4). This
suggests that the tissue-specific expression of Hnf1a is
regulated epigenetically by DNA methylation-dependent gene
silencing.
DISCUSSION
In this study, we applied a recently established method,
D-REAM, to comprehensively analyze the DNA methylation
profiles in the genomic region around the TSS of almost all
mouse SLC transporter genes in the liver and kidney. A
number of SLC transporters were identified as candidate
genes under epigenetic regulation mediated by DNA
methylation. These included both liver- and kidney-specific
transporters. In this study, we focused on the kidney-specific
transporters that are activated potentially by Hnf1a.
Analysis with D-REAM and bisulfite genomic sequencing
mapped the T-DMRs, which were hypomethylated in the
kidney but hypermethylated in the liver, in the 50-upstream
and intronic region of amino-acid transporter genes
predominantly expressed in the kidney (Figure 2). Further-
more, chromatin immunoprecipitation assays showed that
histone H3 around the TSS of three of the four amino-acid
transporters identified in D-REAM (Slc6a19, Slc6a20, and
Slc7a9) was hyperacetylated in the kidney compared with the
liver (Figure 3). As these DNA methylation and histone H3
acetylation profiles were consistent with the tissue distribu-
tion, it is plausible that these amino-acid transporter genes
are subjected to DNA methylation-dependent gene silencing
through direct or indirect interference in the interaction of
transcription factors with the promoter region, leading to
their tissue-specific expression. Histone H3 was acetylated
to the same extent in the liver and kidney around the TSS of
Slc7a8, which might be ascribed to the smaller difference in
the mRNA expression of this gene between the two tissues
(4.5-fold) compared with other amino-acid transporters of
which expression in the kidney is at least 37-fold higher than
that in the liver (Figure 1). rBAT/Slc3a1 and b0,þLAT1/Slc7a9
function together as a heteromeric transporter.22,23 T-DMRs
were mapped around the TSS of both subunits, which may
explain the formation of this heteromeric transporter
predominantly in the kidney. On the other hand, for
4F2hc/Slc3a2 and yþLAT1/Slc7a7 or LAT2/Slc7a8, which
also form a heterodimer in the kidney, only the upstream
region of Slc7a7 and Slc7a8 contained the T-DMR. The
absence of the T-DMR in 4F2hc/Slc3a2 is reasonable
considering its ubiquitous tissue distribution, including
within tumors. We note that the location of the T-DMR
differs between the amino-acid transporters. Thus, it remains
unknown whether gene silencing in the liver is achieved by
the common mechanism.
Hnf1a likely acts as a master regulator for the transcrip-
tion of amino-acid transporters in the kidney because Hnf1a-
null mice manifest a defect in the renal reabsorption of
amino acids,15 and all the major amino-acid transporters in
mice contain the canonical HNF1-binding motifs within
1.0 kbp of their promoter regions (Table 1). Intriguingly,
D-REAM also showed the presence of T-DMR tags in the
liver-specific SLC transporters, including Ntcp/Slc10a1 and
Oatp1b2/Slco1b2 (Table 1). Subsequent bisulfite genomic
sequencing revealed that the genomic regions around the TSS
of these two transporters comprise T-DMR hypomethylated
in the liver.24 Microarray analysis of the expression of hepatic
genes in wild-type and Hnf1a-null mice showed that Ntcp/
Slc10a1 and Oatp1b2/Slco1b2 are downregulated in Hnf1a-
null mice, suggesting a positive regulation by Hnf1a.13
Furthermore, T-DMR was also located in the proximal
promoter region of Hnf1a, which was hypomethylated in the
liver and kidney but hypermethylated in the cerebrum


























Figure 1 |mRNA expression of solute carrier (SLC) transporters
with the tissue-dependent differentially methylated regions
(T-DMR) tag and hepatocyte nuclear factor 1 (HNF1)-binding
motif. The mRNA expression levels of SLC transporters with the
T-DMR tag and HNF1-binding motif in the liver and kidney are
expressed on a logarithmic scale. The open circles represent SLC
transporters with T-DMR tags hypomethylated in the liver and
hypermethylated in the kidney, and the closed circles represent
those with T-DMR tags hypomethylated in the kidney and
hypermethylated in the liver. The solid line indicates a 1:1 ratio
and the dotted lines indicate a 1:2 or 2:1 ratio in the expression
level between the two tissues. The names of transporters with
more than twofold higher expression in one tissue than the other
are given above each circle.
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Figure 2 |DNA methylation profiles of amino-acid transporters. (a) DNA methylation status of CpG dinucleotides neighboring the tissue-
dependent differentially methylated regions (T-DMR) tags. Top, restriction tag-mediated amplification (D-REAM) and subsequent bioinformatic
analysis were carried out and the analyzed data for Slc6a19, Slc6a20, Slc7a8, and Slc7a9were visualized with integrated genome browser (IGB). The
arrowheads and vertical bars represent T-DMR tags and HpyCH4IV sites, respectively. The comparative signals between the kidney (K) and liver
(L) are indicated as plots, and gray bars indicate the significantly different regions. Bottom, bisulfite genomic sequencing was performed with
genomic DNA extracted from mouse liver and kidney focusing on the region encompassing the T-DMR tags as described in Materials and
Methods. The numbers indicate the positions of cytosine residues of the CpG dinucleotides relative to the transcription start site of the reference
sequence transcript (þ 1). The open and closed circles represent unmethylated and methylated cytosines, respectively. (b) Comparative D-REAM
signals for other amino-acid transporters. Top, comparative D-REAM signals were examined for the whole genomic region of Slc1a1, Slc3a1,
Slc3a2, and Slc7a7, and visualized with IGB. Bottom, bisulfite genomic sequencing was performed as described in (a).
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its tissue distribution,25 suggesting that the master regulator
itself also undergoes epigenetic regulation in addition to the
downstream effector molecules, such as amino-acid trans-
porters and xenobiotic transporters.
Taken together, our present findings illustrate the multi-
layered mechanism responsible for the transcriptional
regulation of liver- and kidney-specific transporters
(Figure 5). First, DNA methylation-dependent gene silencing
confines the expression of the master regulator Hnf1a
predominantly in the liver and kidney. Second, DNA
methylation and histone acetylation profiles in the down-
stream direction allow Hnf1a to activate a distinct set
of effector molecules exclusively in the liver or kidney,
which is crucial to constitute the hepatic or renal function.
This cascade would have the advantage of excluding
redundancy in the regulatory system for the tissue-specific
gene expression.
The significance of amino-acid transporters in the renal
reabsorption process is supported clinically by the observa-
tions that genetic defects in these transporters are associated
with various types of inherited aminoaciduria.21 B0AT1/
SLC6A19 is the causative gene for Hartnup disorder. The
genetic mutations in two pairs of heteromeric trans-











































































































Figure 3 |Histone acetylation profiles around the transcriptional start sites of amino-acid transporters. The histone H3 acetylation
status around the transcriptional start sites of Slc6a19, Slc6a20, Slc7a8, Slc7a9, and b-actin was determined by chromatin immunopre-
cipitation assay in mouse liver and kidney as described in Materials and Methods. The closed columns represent the histone acetylation of
each sample relative to its respective total input. Normal rabbit IgG was included as a negative control to verify the immunoprecipitation

















Figure 4 |DNA methylation profile of Hnf1a promoter. Top, a
schematic diagram of the 50-flanking region of Hnf1a. The vertical
lines and numbers indicate the positions of cytosine residues
of the CpG dinucleotides relative to the transcription start site
(þ 1). Bottom, DNA methylation status of individual CpG
dinucleotides. Bisulfite genomic sequencing was performed with
genomic DNA extracted from mouse liver, kidney, and cerebrum.
The open and closed circles represent unmethylated and
methylated cytosines, respectively.
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LAT1/SLC7A7, are prevalent in patients with cystinuria and
lysinuric protein intolerance, respectively. EAAC1/SLC1A1,
XT3/SLC6A20, and LAT2/SLC7A8 are also candidate genes
that are functionally perturbed in dicarboxylic aminoaciduria,
iminoglycinuria, and isolated cystinuria, respectively. It
would be fascinating to know whether T-DMRs are involved
in the kidney-specific expression of these amino-acid
transporters in humans as in mice.
In conclusion, this study has emphasized the common
characteristics associated with the kidney-specific expression
of amino-acid transporters, that is, the presence of T-DMR
hypomethylated in the kidney compared with the liver and
HNF1-binding motif in the promoter region. These findings
suggest the role of T-DMRs in the tissue-specific transcrip-
tional regulation by Hnf1a.
MATERIALS AND METHODS
Materials
All reagents were purchased from Wako Pure Chemicals (Osaka,
Japan) unless stated otherwise.
T-DMR profiling with restriction tag-mediated amplification
D-REAM and subsequent bioinformatic analysis were carried out as
described previously for the genomic DNA from the liver and
kidney of C57BL/6NCrj male mice at 12 or 13 weeks of age.18
Briefly, the genomic DNA was digested with a methylation-sensitive
restriction enzyme HpyCH4IV that recognizes ACGT residues and
subsequently amplified by modified ligation-mediated PCR. As
HpyCH4IV digests only the unmethylated DNA, the modified
ligation-mediated PCR facilitates the selective amplification of
the unmethylated region in the genomic DNA. The amplified
fragments were then hybridized with a mouse promoter-tiling array,
and the array signal intensities were analyzed to identify regions
corresponding to fragments in unmethylated HpyCH4IV sites.
Comparison of signals from different samples enabled the
identification of differentially methylated regions. T-DMR tag
is defined as a differentially methylated HpyCH4IV restriction
site between tissues. Genomic annotations including Ensembl
gene assignments were performed on the Galaxy website
(http://main.g2.bx.psu.edu/).26 The analyzed data were then visua-
lized using integrated genome browser (http://www.affymetrix.com/
support/developer/tools/download_igb.affx).
In silico analysis
The mRNA expression levels of mouse SLC transporters were
obtained from the public database GNF SymAtlas (http://syma-
tlas.gnf.org/SymAtlas/).27 SLC transporter genes with potential
HNF1-binding motifs in the 50-flanking region up to 1.0 kbp
relative to the TSS were identified using g:Profiler (http://
biit.cs.ut.ee/gprofiler/),28 and the position of each motif was
determined further by a computer-based approach with MatIn-
spector (http://www.genomatix.de/).
Bisulfite genomic sequencing
Genomic DNA from the liver, kidney, and cerebrum of C57BL/
6NCrj 11-week-old male mice was extracted using a Get Pure DNA
Kit (Dojindo Molecular Technologies, Gaithersburg, MD, USA)
according to the manufacturer’s instructions. In all, 2 mg of genomic
DNA was digested with BamHI and subjected to the bisulfite
reaction as described previously, and the purified DNA was
resuspended in 10mM Tris-HCl and 1mM EDTA, pH 8.0.9 The
DNA fragments encompassing the T-DMR tag of the Slc3a1,
Slc6a19, Slc6a20, Slc7a8, and Slc7a9 genes were amplified by PCR
using the primers listed in Table 2. PCR was performed using
Immolace DNA Polymerase (Bioline, London, UK) under the
following conditions: 94 1C for 10min; 43 cycles of 94 1C for 30 s,
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Figure 5 |Multilayered mechanism for the transcriptional regulation of kidney-specific transporters. DNA methylation determines
both the tissue distribution of the master regulator Hnf1a and its interaction with downstream effector molecules, thereby establishing and
maintaining the kidney-specific transport systems. The same scheme should apply to the liver-specific transporters with opposite DNA
methylation profiles in the downstream direction. See text for details.
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30 s, and 72 1C for 1min; final extension at 72 1C for 10min. The
proximal promoter region of Hnf1a was amplified with the primers
listed in Table 2 under the following conditions: 95 1C for 7min; 40
cycles of 94 1C for 1min, 60 1C for 30 s, and 72 1C for 1min;
final extension at 72 1C for 10min. The PCR products were
cloned into pGEM-T Easy vector (Promega, Madison, WI, USA),
and 6–16 clones were chosen randomly from each sample and
sequenced to determine the presence of methylated cytosines.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation assay was performed in the
liver and kidney of C57BL/6NCrj male mice using anti-acetylated
histone H3 antibody (Upstate Biotechnology, Lake Placid, NY, USA)
or normal rabbit IgG (negative control) as described previously.24
The quantitative real-time PCR was performed using 7900HT Fast
Real-Time PCR System (Applied Biosystems, Foster City, CA, USA)
and SDS Software version 2.3 according to the manufacturer’s
instructions with the primers shown in Table 2. The protocol for
PCR was as follows: 50 1C for 2min; 95 1C for 10min; 40 cycles of
95 1C for 15 s and 60 1C for 1min. The enrichment of DNA in the
immunoprecipitates was calculated relative to the 1:100 diluted
‘total input’ samples.
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